Millendo Therapeutics begins human trial of VMS drug candidate MLE-301
Millendo Therapeutics has started a phase 1 clinical trial of its selective neurokinin 3 receptor (NK3R) antagonist MLE-301, which is being developed for the treatment ... Read More
Millendo Therapeutics finalizes merger with OvaScience, strengthens rare disease pipeline
Millendo Therapeutics has finalized its merger with OvaScience, a Massachusetts-based biotech firm specializing in female infertility treatments. The transaction, initially announced in August 2018, concludes ... Read More